solanezumab discontinued
Selected indexed studies
- Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. (Lancet Neurol, 2025) [PMID:40120616]
- Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease. (Expert Opin Biol Ther, 2018) [PMID:30376649]
- Passive antiamyloid immunotherapy for Alzheimer's disease. (Curr Opin Psychiatry, 2020) [PMID:32040044]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. (2025) pubmed
- Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial. (2025) pubmed
- Passive antiamyloid immunotherapy for Alzheimer's disease. (2020) pubmed
- Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. (2022) pubmed
- Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? (2014) pubmed
- Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease. (2018) pubmed
- Clinical pharmacology of novel anti-Alzheimer disease modifying medications. (2013) pubmed
- A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's disease. (2015) pubmed